Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2305–2328 of 35,409 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Pembrolizumab; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 533
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 340 more

Conditions: Pain
Interventions: bupivacaine liposome injectable suspension, Placebo; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 14
States / cities: Mobile, Alabama • Englewood, Colorado • Miami, Florida + 9 more

Conditions: Healthy
Interventions: Atorvastatin, MGL-3196; Drug
Lead sponsor: Madrigal Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Depression, Mild Cognitive Impairment
Interventions: IV Ketamine; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 50 Years to 90 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer
Interventions: 5-Fluorouracil, Leucovorin (LV), Gamma-Interferon-1b (IFN-γ), Bevacizumab; Drug
Lead sponsor: Accelerated Community Oncology Research Network; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Anterior Cruciate Ligament Injuries
Interventions: Opiate Sparing, Opiate Based; Drug
Lead sponsor: Campbell Clinic; Other
Eligibility: 14 Years to 85 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Skokie, Illinois • Cincinnati, Ohio • Memphis, Tennessee

Conditions: End Stage Renal Disease, Inflammation
Interventions: Not listed
Lead sponsor: Fresenius Medical Care North America; Industry
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 2
States / cities: Waltham, Massachusetts

Conditions: Patient-centered Outcomes Research, Surgery
Interventions: Immersive Preoperative Experience; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Bladder Cancer
Interventions: Blood draw; Genetic
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: New York, New York

Conditions: HIV Infections
Interventions: BufferGel, PRO 2000/5 Gel, Placebo gel; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 3,101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hunger
Interventions: psyllium fiber 6.8g, placebo; Dietary Supplement
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: PF-07261271, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Lake Forest, California • Tustin, California • Eatontown, New Jersey + 1 more

Conditions: Seizures, Epilepsy
Interventions: Ear-SD, Electroencephalogram; Device · Diagnostic Test
Lead sponsor: Felicia Chu; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2032
U.S. locations: 2
States / cities: Worcester, Massachusetts

Conditions: Healthy Lifestyle Behaviors, Depressive/Anxiety Symptoms
Interventions: COPE/Healthy Lifestyles TEEN Program., Healthy Teens Attention Control Program; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 14 Years to 16 Years
Enrollment: 1,219 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Sleep
Interventions: LED portable light therapy bulb; Other
Lead sponsor: Colorado State University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Cannabis Use
Interventions: No Warning Control, Delayed Effects Text Only, Delayed Effects Plus Icon, Delayed Effects Plus Dose, Delayed Effects Plus Dose Plus Adverse Effects; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1,250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy
Interventions: Memantine, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Rhinoplasty, Pain Management
Interventions: Liposomal Bupivacaine, 0.25% bupivacaine with 1:200,000 epinephrine, Placebo - Saline solution; Drug · Other
Lead sponsor: Jessyka Lighthall; Other
Eligibility: 18 Years to 99 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Brain and Central Nervous System Tumors, Breast Cancer, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Lymphoma, Melanoma (Skin), Neoplastic Syndrome
Interventions: yttrium Y 90-edotreotide; Radiation
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Kidney Diseases, Kidney Injury, Kidney Failure
Interventions: MB-102, MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR); Drug · Device
Lead sponsor: MediBeacon; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Chicago, Illinois • Columbus, Ohio • Austin, Texas + 1 more

Conditions: Health Adult Subjects, Obesity & Overweight
Interventions: TIX100, Placebo; Drug
Lead sponsor: TIXiMED, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Primary Immune Deficiency Disorders, Hemophagocytic Lymphohistiocytosis, Inherited Bone Marrow Failure Syndrome, Hemoglobinopathies, Metabolic Disorders
Interventions: BPX-501 and Rimiducid; Biological
Lead sponsor: Bellicum Pharmaceuticals; Industry
Eligibility: 4 Months to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pituitary Macroadenoma
Interventions: intra-operative MRI, Transsphenoidal resection of pituitary macroadenoma; Other · Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Cardiovascular Health
Interventions: Lychee Fruit Extract; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Davis, California

Search by objective public record fields.

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty

Drug Interaction Study of MGL-3196 With Atorvastatin

Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

Study of Gamma Interfereon in Metastatic Colorectal Carcinoma

Reduce Opiate Exposure With ACL Surgery

Inflammation and Nutritional Parameters in Hemodialysis Patients Using Reprocessed Dialyzers

Preoperative Immersive Patient Quality Experience

A 12-Gene Blood-Based Signature for Detecting Metastatic Bladder Cancer

BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women

Study of Psyllium 6.8 g Versus Placebo on Satiety in Healthy Volunteers

A Study to Learn About Study Medicine Called PF-07261271 in Healthy People

Ear-Seizure Detection (EarSD) Study

COPE/Healthy Lifestyles for Teens: A School-Based RCT

Effects of Combined Blue and Red Home-Based Light Therapy on Sleep in Adults With Self-Reported Sleep Difficulties

Perceptions of Proposed Warnings for Cannabis Edibles Packaging

Functional Neuroimaging of Alcoholism Vulnerability (PIT)

Efficacy of Liposomal Bupivacaine Post Septorhinoplasty

Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

Utilization of iMRI for Transsphenoidal Resection of Pituitary Macroadenomas

Pilot Study of Lychee Fruit Extract to Promote Cardiovascular Health